Withdrawn from sale[edit | edit source]
In 2004, rofecoxib was voluntarily withdrawn from sale by manufacturer Merck because of safety concerns about the increased risk of stroke and heart attack when high doses are used for the long term.
Side effects[edit | edit source]
Using nonsteroidal anti-inflammatory precautions is recommended to avoid gastrointestinal side effects. Hepatic and renal dysfunction may occur, and peripheral edema. Central nervous system side effects include "dizziness, headaches, drowsiness and evidence of hypersensitives." 
More commonly reported ones are:
- Gastrointestinal side-effects including bleeding.
More commonly reported ones in children are:
Less commonly reported ones are:
Evidence[edit | edit source]
Before being withdrawn from the market Rofecoxib was listed as a suggested drug in the Canadian Consensus Criteria for ME/CFS, but it was not highlighted as better in any way in comparison to celecoxib or other NSAIDs.
Dose[edit | edit source]
A dose of 12.5 to 25 mg daily, if needed, was suggested by the Canadian Consensus Criteria.
Learn more[edit | edit source]
- Rofecoxib - DrugBank
See also[edit | edit source]
References[edit | edit source]
- "Rofecoxib". www.drugbank.ca. Retrieved Apr 27, 2019.
- Carruthers, Bruce M.; Jain, Anil Kumar; De Meirleir, Kenny L.; Peterson, Daniel L.; Klimas, Nancy G.; Lerner, A. Martin; Bested, Alison C.; Flor-Henry, Pierre; Joshi, Pradip; Powles, A C Peter; Sherkey, Jeffrey A.; van de Sande, Marjorie I. (2003). "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Clinical Working Case Definition, Diagnostic and Treatment Protocols" (PDF). Journal of Chronic Fatigue Syndrome. 11 (2): 55.